Filing Flows › Health Care › AbbVie (ABBV)
AbbVie (ABBV) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · AbbVie (ABBV) Q3 2026 earnings results →
Q3 2026 Revenue up 10% year over year to $17.4B · 24¢ of every $1 of revenue kept as net profit · operating margin 36.0%
AbbVie made $17.4B in Q3 2026 (+10% Y/Y). Operating margin 36.0%, net earnings $4.2B. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $17.4B in Q3 2026, up 10% year over year and up 2% from the previous quarter.
Operating profit was $6.3B, a 36.0% margin (up 23.9 points year over year). Of the extra revenue versus Q3 2025, 268% reached operating profit, above the 12% margin then. Total costs fell 20% while revenue rose 10%. The fastest-growing cost line was SG&A (+15%). Net earnings were $4.2B, up 2168% year over year. The effective tax rate was 12.6%.
Operating cash flow was $7.6B (up 8% year over year), 180% of net earnings. Non-cash charges added back $1.9B of depreciation and amortization and $0.16B of share-based compensation. Working capital and other items added $1.3B. Capital expenditures of $0.30B left free cash flow of $7.3B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $17.4B | +10% | 36.0% | $4.2B | $7.6B |
| Q2 2026 | 10-Q | Aug 3, 2026 | $17.0B | +10% | 37.9% | $3.6B | $3.4B |
| Q1 2026 | 10-Q | May 8, 2026 | $15.0B | +12% | 26.6% | $697M | $3.8B |
| Q4 2025 | 10-K | Feb 20, 2026 | $16.6B | +10% | 27.3% | $1.8B | $5.2B |
| Q3 2025 | 10-Q | Nov 4, 2025 | $15.8B | +9% | 12.1% | $188M | $7.0B |
| Q2 2025 | 10-Q | Aug 4, 2025 | $15.4B | +7% | 31.7% | $941M | $5.2B |
| Q1 2025 | 10-Q | May 9, 2025 | $13.3B | +8% | 28.0% | $1.3B | $1.6B |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
Buys from
About AbbVie
AbbVie or "the company" refer to AbbVie Inc., or AbbVie Inc. and its consolidated subsidiaries, as the context requires. AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.
In its own words, from its 10-K, filed Feb 20, 2026.
AbbVie against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +7%. Operating margin: 36.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
| TEVA Teva Pharmaceutical Industries | Q3 2026 | $4.4B | -2% | 16.2% |
Source: AbbVie 10-Q on SEC EDGAR · CIK 1551152 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns ABBV and who is buying
More on ABBV
- How AbbVie makes money: revenue by segment
- AbbVie next earnings date and what analysts expect
- AbbVie stock forecast, price target and fair value
- Who owns AbbVie stock: holders, funds and Congress trades
- AbbVie guidance and outlook
- Is AbbVie a takeover target? LBO and rumors
- AbbVie recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results